Table 2

Baseline mean HbA1c, baseline mean fasting plasma glucose (FPG), percentage of known diabetes and diabetes duration

Study, year	Study group	Baseline mean HbA1 (%)	Baseline mean FPG (mmol/L)	Percentage of known diabetes	Diabetes duration (year)
Budania et al,8 2013	Ranolazine	n/a	7.8	100	n/a
Budania et al,8 2013	Placebo	n/a	7.2	100	n/a
Eckel et al,18 2015	Ranolazine	8.1	9.6	100	3
Eckel et al,18 2015	Placebo	8.0	9.6	100	3
Kipnes et al, 19 2011	Ranolazine	8.4	8.6	100	8.7
Kipnes et al, 19 2011	Placebo	8.5	9.6	100	9.7
Kosiborod et al,9 2013	Ranolazine	7.3		100	7.2
Kosiborod et al,9 2013	Placebo	7.3		100	7.7
Morrow et al, 2009	Ranolazine	6.2 (all) 7.5 (diabetic)	n/a	33.1	n/a
Morrow et al, 2009	Placebo	6.2 (all) 7.5 (diabetic)	n/a	35.3	n/a
Pettus et al, 2015 – glimepiride add-on study	Ranolazine	9.8	9.8	100	7.1
Pettus et al, 2015 – glimepiride add-on study	Placebo	9.8	9.8	100	7
Pettus et al, 2015 – metformin add-on study	Ranolazine	9.4	9.4	100	6.4
Pettus et al, 2015 – metformin add-on study	Placebo	9.4	9.4	100	6.7
Timmis et al, 2005	Ranolazine 1000 mg twice daily	7.92	9.2 (n=57, diabetic)	100	n/a
	Ranolazine 750 mg twice daily	7.65	9.4 (n=63, diabetic)	100	n/a
	Placebo	7.46	9.9 (n=49, diabetic)	100	n/a